Inj, amivantamab-vmjw
Products billed under this code include Rybrevant.
Payment limit per 2 MG, by effective quarter, 1Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Rybrevant.
Payment limit per 2 MG, by effective quarter, 1Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Rybrevant | Janssen Biotech, Inc. | 57894-0501-01 | 175 | $4,133.85 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $23.622 | +$0.403 | 2 MG | Inj, amivantamab-vmjw | v1, posted September 17, 2026 |
| 3Q26 | $23.219 | +$0.588 | 2 MG | Inj, amivantamab-vmjw | v1, posted September 15, 2026 |
| 2Q26 | $22.631 | +$0.076 | 2 MG | Inj, amivantamab-vmjw | v1, posted September 15, 2026 |
| 1Q26 | $22.555 | +$0.015 | 2 MG | Inj, amivantamab-vmjw | v1, posted September 15, 2026 |
| 4Q25 | $22.54 | +$0.333 | 2 MG | Inj, amivantamab-vmjw | v1, posted September 8, 2026 |
| 3Q25 | $22.207 | +$0.70 | 2 MG | Inj, amivantamab-vmjw | v1, posted March 10, 2026 |
| 2Q25 | $21.507 | −$0.051 | 2 MG | Inj, amivantamab-vmjw | v1, posted March 10, 2026 |
| 1Q25 | $21.558 | +$0.885 | 2 MG | Inj, amivantamab-vmjw | v1, posted December 19, 2025 |
| 4Q24 | $20.673 | +$0.104 | 2 MG | Inj, amivantamab-vmjw | v1, posted June 11, 2025 |
| 3Q24 | $20.569 | +$0.584 | 2 MG | Inj, amivantamab-vmjw | v1, posted June 11, 2025 |
| 2Q24 | $19.985 | +$0.01 | 2 MG | Inj, amivantamab-vmjw | v1, posted March 11, 2025 |
| 1Q24 | $19.975 | −$0.013 | 2 MG | Inj, amivantamab-vmjw | v1, posted December 19, 2024 |
| 4Q23 | $19.988 | +$0.357 | 2 MG | Inj, amivantamab-vmjw | v1, posted October 10, 2024 |
| 3Q23 | $19.631 | −$0.049 | 2 MG | Inj, amivantamab-vmjw | v1, posted June 5, 2024 |
| 2Q23 | $19.68 | +$0.677 | 2 MG | Inj, amivantamab-vmjw | v1, posted February 23, 2024 |
| 1Q23 | $19.003 | +$0.105 | 2 MG | Inj, amivantamab-vmjw | v1, posted December 6, 2023 |
| 4Q22 | $18.898 | +$0.235 | 2 MG | Inj, amivantamab-vmjw | v1, posted June 22, 2023 |
| 3Q22 | $18.663 | +$0.767 | 2 MG | Inj, amivantamab-vmjw | v1, posted June 9, 2023 |
| 2Q22 | $17.896 | −$0.009 | 2 MG | Inj, amivantamab-vmjw | v1, posted December 14, 2022 |
| 1Q22 | $17.905 | – | 2 MG | Inj, amivantamab-vmjw | v1, posted June 8, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.